Trial Profile

Randomized Phase II Trial of S-1 Versus S-1 plus Oxaliplatin (Sox) in Patients with Gemcitabine Refractory Pancreatic Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jun 2017 Results of pooled analysis of three studies including this study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
31 May 2013 According to a Yakult Honsha media release, the company has submitted supplemental new drug applications relating to an additional indication for pancreatic cancer, with respect to its products, Campto (40mg and 100mg), Elplat (50mg, 100mg and 200mg), and Levofolinate [Yakult] (25mg and 100mg), to the Japanese Ministry of Health, Labor and Welfare (MHLW).
30 Oct 2012 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com